ZLZydus Lifesciences532321New partnership deal

Zylidac Bio and Prolific Machines partner to scale Prolific's light-controlled biologics platform to GMP production

Zylidac Bio, the Zydus group's biologics CDMO, and Prolific Machines announced on 21 October 2026 a partnership to scale Prolific's cell line platform to GMP production at Emeryville, California.

By ScoutQuest · Wed 21 Oct 2026, 6:28 PM IST · 1 min read

Tech transfer scale

50-liter tech transfer

Scale-up target

250 liters and GMP manufacturing

Productivity milestone

21 g/L in a 15-day intensified fed-batch CHO run for a monoclonal antibody at small scale

Release

Deal / acquisition

📌 Prolific's illumination hardware will work with Zylidac's existing bioreactors, which the companies say eliminates the need for customers to build new manufacturing infrastructure.

📌 The partnership is designed to give Prolific's clients an end-to-end pathway from cell line development at Prolific to drug substance and drug product manufacturing, fill-finish and packaging at Zylidac in Emeryville.

📌 Prolific has reported a productivity milestone of 21 g/L in a 15-day intensified fed-batch CHO run for a monoclonal antibody at small scale, and says its platform delivers up to three-fold titer increases for other complex formats.

📌 Deniz Kent, Chief Executive Officer and Co-Founder of Prolific, said the next step is scaling the technology to GMP production for clinical and commercial supply.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev